TDOC vs. HIMS, APGE, NARI, VERA, GERN, ARVN, DYN, PRVA, GH, and DNLI
Should you be buying Teladoc Health stock or one of its competitors? The main competitors of Teladoc Health include Hims & Hers Health (HIMS), Apogee Therapeutics (APGE), Inari Medical (NARI), Vera Therapeutics (VERA), Geron (GERN), Arvinas (ARVN), Dyne Therapeutics (DYN), Privia Health Group (PRVA), Guardant Health (GH), and Denali Therapeutics (DNLI). These companies are all part of the "medical" sector.
Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
In the previous week, Teladoc Health had 12 more articles in the media than Hims & Hers Health. MarketBeat recorded 28 mentions for Teladoc Health and 16 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.15 beat Teladoc Health's score of -0.03 indicating that Teladoc Health is being referred to more favorably in the news media.
Hims & Hers Health has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Teladoc Health has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 31.6% of Hims & Hers Health shares are held by company insiders. Comparatively, 1.0% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Hims & Hers Health currently has a consensus price target of $14.85, suggesting a potential upside of 31.85%. Teladoc Health has a consensus price target of $18.73, suggesting a potential upside of 46.58%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Teladoc Health is more favorable than Hims & Hers Health.
Teladoc Health received 643 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 63.47% of users gave Teladoc Health an outperform vote while only 34.21% of users gave Hims & Hers Health an outperform vote.
Hims & Hers Health has higher earnings, but lower revenue than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of -2.70% compared to Hims & Hers Health's net margin of -8.90%. Teladoc Health's return on equity of -7.21% beat Hims & Hers Health's return on equity.
Summary
Teladoc Health beats Hims & Hers Health on 9 of the 17 factors compared between the two stocks.
Get Teladoc Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TDOC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teladoc Health Competitors List
Related Companies and Tools
